Genedrive Share News (GDR)

UK earnings, trading statements calendar - next 7 days

IN BRIEF: Genedrive to receive GBP1.2 million grant for test kit

Genedrive PLC - Manchester-based molecular diagnostics company - Confirms that it expects to benefit from GBP1.2 million of funding, through its participation in a multi-partner grant award from Innovate UK and the UK government Innovation Accelerator programme. The grant, which is for the development and validation of technology for time critical genomic testing, will provide Genedrive with acute care patient access and supporting infrastructure to assess the real world clinical performance of time-critical clinical tests in NHS settings.

Genedrive appoints new chief executive and chief scientific officer

(Alliance News) - Genedrive PLC on Monday said it appointed James Cheek as its new chief executive officer, effective immediately.

Genedrive diagnostic test system gets UKCA registration

(Sharecast News) - Point-of-care molecular diagnostics developer Genedrive announced on Wednesday that its Genedrive CYP2C19 System has received UKCA marking registration.

Genedrive shares jump as hails UKCA mark for test; aims for EU CE mark

(Alliance News) - Genedrive PLC on Wednesday said that its CYP2C19 point of care test achieved marking registration in the UK, known as UKCA.

TRADING UPDATES: RTW plans buyback; Octopus AIM VCTs eye fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Genedrive draws down £0.3m under equity prepayment facility

(Sharecast News) - Molecular diagnostics company Genedrive announced the latest drawdown of £0.3m under its £5m equity prepayment facility on Wednesday.

Genedrive secures multi-partner grant award

(Sharecast News) - Molecular diagnostics specialist Genedrive announced its involvement in a multi-partner grant award called DEVOTE on Friday, supported by Innovate UK and the UK government's Innovation Accelerator programme.

AIM WINNERS & LOSERS: Marlowe up on report of potential division sale

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: Genedrive shares up as UK government grant received

Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Awarded a multi-partner grant for the validation of its CYP2X19 ID kit from Innovate UK and the UK government Innovation Accelerator programme. Says the 'Devote' grant will allow it to offer critical clinical tests in NHS settings.

Genedrive jumps on draft NICE testing guidance

(Sharecast News) - Point-of-care molecular diagnostics company Genedrive announced on Friday that the UK's National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the use of CYP2C19 genotyping before administering clopidogrel in the management of ischemic stroke (IS) patients.

Genedrive says NICE committee recommends CYP2C19 for stroke patients

(Alliance News) - Genedrive PLC on Friday said draft guidance from the UK's National Institute for Health & Care Excellence has recommended that CYP2C19 genotyping should be used to manage ischemic stroke patients.

AIM WINNERS & LOSERS: iEnergizer to depart; Unbound for sale

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

UK shareholder meetings calendar - next 7 days

IN BRIEF: Genedrive sees acceleration of revenue in 2023

Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Reports revenue in the six months to December 31 of GBP20,000 compared to nothing a year prior, and an operating loss of GBP2.7 million from GBP2.8 million. Confident that the company will see an acceleration of revenues through 2023 and going forwards. Agrees GBP5 million equity prepayment facility with Riverfort Global Opportunities PCC Ltd with an initial drawn amount of GBP2 million, expected to be received in early April. Proceeds will be used towards the commercialisation of the antibiotic induced hearing loss test, Genedrive MT-RNR1 ID Kit and enhancing the Genedrive platform as well as providing additional working capital. Directors believe the facility is the best option available at present.